Industry News
Overview of Diabetes Treatment Strategies…
According to the ninth edition of the Diabetes Atlas published by the International Diabetes Federation (IDF), the number of people with diabetes worldwide is estimated to be 463 million in 2…
mRNA Technology: How To Achieve Targeted …
As a new pharmaceutical technology, mRNA has made breakthroughs in the treatment of infectious diseases and tumors in a short time. At present, one of the major obstacles in clinical mRNA tec…
Lipid Nanoparticles (LNP) for mRNA Drug D…
Lipid Nanoparticle (LNP) is currently the dominant mRNA Drug delivery system.
Anti-Obesity Drugs: History And Developme…
Obesity has become a global public health problem. There are much needs for the development of anti-obesity medications.
5 Types of COVID-19 Vaccines
In the context of the COVID-19 global pandemic, vaccination has become the key to controlling the spread of the COVID-19 in the population. Existing COVID-19 vaccines mainly include inactivat…
New FDA Approved Drugs in Q1 2022
With the first three months of 2022 now in the rear-view mirror, the FDA has approved 10 new drugs (Table 1).
Ensitrelvir, A Novel Antiviral Drug Again…
In addition to vaccines, oral antiviral drugs are expected to play an important role in the treatment of COVID-19 caused by severe acute respiratory disease coronavirus-2 (SARS-CoV-2) infecti…
Challenges of Immunotherapy For Prostate …
On March 15, 2022, Merck announced that it would discontinue the KEYLYNK-010 study. Results of interim analysis showed that KEYTRUDA (pembrolizumab) in combination with LYNPARZA (olaparib) fa…
Immunotherapy + mRNA Technology To Treat …
The study found that cancer stem cells in triple-negative breast tumors had low expression of ligand-dependent corepressor (LCOR), which led to their escape from immunotherapy. On this basis,…
COVID-19 Drugs: Small Molecules VS. Antib…
Eleven COVID-19 therapeutic drug therapies are currently available globally, including eight injectable drug therapies and three oral drugs,
sales@huatengusa.com
+86 0731 89916275